New Delhi, Mar 8 (PTI) – India, recognised for hosting one of the largest homoeopathy ecosystems globally, is primed to assume a leadership role in this sector. This shift is underpinned by strong clinical expertise, extensive practitioner networks, and internationally acknowledged quality certifications and standards.
For many years, German homoeopathy brands have been esteemed for their quality, consistency, and research-backed manufacturing practices. However, experts assert that India is not only on a trajectory to match this reputation but may even surpass it, propelled by two robust quality frameworks: the AYUSH Premium Mark and NABL accreditation.
Industry reports indicate that India is home to over 250,000 registered homoeopathy practitioners and nearly 300 educational institutions, with millions of patients relying on homoeopathy as either their primary or complementary medical system. The global homoeopathy market is valued between USD 8 to 10 billion, with Europe representing a substantial share, historically led by Germany. Experts believe that Indian brands, supported by quality assurances, are well-positioned to contest this dominance.
Dr Pradeep Prajapati, Director of the All India Institute of Ayurveda (AIIA), emphasises that the key differentiating factor lies in certified quality and scientific validation. He explains that the AYUSH Premium Mark, introduced by the Ministry of AYUSH, signifies compliance with global standards in manufacturing, safety, and quality management for AYUSH products.
The NABL (National Accreditation Board for Testing and Calibration Laboratories) certification guarantees accuracy, reliability, and reproducibility in testing and quality control, aligned with internationally recognised ISO standards. Rajeshwar Tiwari, a senior representative from the Ministry of AYUSH, notes that India possesses unparalleled clinical data, practitioner strength, and patient diversity in homoeopathy.
“When this experiential advantage is complemented by certified quality frameworks like AYUSH Premium and NABL, Indian homoeopathy acquires scientific credibility that is comparable globally. This integration of research, regulation, and manufacturing excellence is crucial for competing with established European brands,” Tiwari states.
A significant illustration of this transformative shift is Adven Biotech, which has become the first homoeopathy company in India to receive both the AYUSH Premium Mark and NABL certification. Adesh Sharma, CEO of Adven Biotech, describes these certifications as global passports for Indian homoeopathy.
Sharma explains, “For years, Indian brands were clinically robust but undervalued on the international stage due to a lack of globally recognised quality benchmarks. These certifications change that perception entirely and position Indian companies on an equal footing with leading German manufacturers.” He further asserts that India stands to gain strategically, stating, “Germany may have legacy, but India possesses scale, talent, raw material strength, and now certified quality. When Indian brands merge NABL-backed testing accuracy with AYUSH Premium manufacturing standards, we can provide products that are globally trusted yet significantly more accessible. This is how India does not merely compete with German homoeopathy; we excel beyond it.”
Sharma adds, “We aligned our internal systems with international norms—from raw material authentication and in-process checks to final product validation. NABL encouraged us to measure everything scientifically, while AYUSH Premium ensured holistic compliance across manufacturing and governance. It was challenging, but it has transformed our organisation.” Experts highlight that such transformations are critical as global consumers become increasingly discerning. Markets in Europe, the Middle East, Latin America, and Africa are demanding evidence of quality, safety, and consistency, moving beyond traditional perceptions.
Dr Prajapati notes, “German brands have historically benefitted from strong regulatory backing and standardised pharmacopoeia. However, India is swiftly closing that gap.” From an economic perspective, he adds that the opportunity is significant, as India already exports homoeopathic medicines to over 100 countries, while premium markets in Europe have remained relatively underrepresented by Indian brands.
With internationally aligned certifications, experts project that Indian homoeopathy exports could potentially grow two to three times within the next five to seven years, particularly in regulated markets. Dr Prajapati mentions, “Another major advantage India holds over Germany is cost-efficiency without compromising quality.”
In the coming years, experts anticipate that the competition with German brands will centre not on legacy but on the ability to deliver the most reliable, transparent, and globally compliant homoeopathic solutions. With the AYUSH Premium and NABL certifications serving as robust foundations, India appears ready not only to stand alongside Germany but to lead the next chapter of global homoeopathy,” Dr Prajapati concludes.